Sydney, Australia – 21 February 2024 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received $1,900,000 from Radium Capital under a funding facility secured against Radiopharm’s anticipated FY24 Research and Development Tax Incentive (RDTI).
The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.
For more information, download the attached PDF.
Download this document
